Latigo Biotherapeutics Inc.

LTGO

Healthcare|Medical - Pharmaceuticals|US

$12.60

-0.41 (-3.15%)

Clinical Trials (9)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT06049095 A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants	Healthy	P1	Active	204	RCT, Double-blind	LTG-001, Placebo
NCT07102459 An Efficacy and Safety Study of LTG-001 Following Abdominoplasty	Acute Pain, Postoperative Pain Control	P2	Completed	343	RCT, Double-blind	Experimental: LTG-001 High Dose, Experimental: LTG-001 Low Dose, Active Comparator: HB/APAP, Placebo Comparator
NCT06774625 This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars	Acute Pain, Postoperative	P2	Completed	250	RCT, Double-blind	LTG-001 High Dose, LTG-001 Mid Dose, LTG-001 Low Dose, Suzetrigine
NCT07341152 A Study Comparing LTG-001 SDD Formulation To LTG-001 Crystalline Immediate Release Tablets In Healthy Participants	Pain Management	P1	Completed	14	RCT, Open-label	LTG-001 SDD, LTG-001 Formulation A Prototype 1, LTG-001 Formulation B Prototype 2, LTG-001 Formulation B prototype 2
NCT07915947 LTG-321 - Itraconazole Drug-drug Interaction (DDI) Study	PK Drug-drug Interaction Study	P1	Not Yet Recruiting	28	RCT, Open-label	LTG-321, Itraconazole (200 mg)
NCT07110610 Phase 1 Single and Multiple Ascending Dose of LTG-321 in Healthy Participants	Healthy Participants	P1	Completed	112	RCT, Double-blind	LTG-321
NCT06554574 A Phase 1 Single and Multiple Ascending Dose Study of LTG-305 Administered Orally in Healthy Participants	Healthy	P1	Completed	112	RCT, Double-blind	LTG-305
NCT06600607 Pharmacodynamic Study of 300mg Pregabalin vs Placebo in Healthy Male Adults	Pain Detection, Pain Threshold	Early P1	Completed	20	RCT, Double-blind	pregabalin 300 mg
NCT06972212 Pharmacodynamic Study of 100mg Suzegtrigine vs Placebo in Healthy Male Adults	Pain Detection, Pain Threshold	Early P1	Completed	20	RCT, Double-blind	suzetrigine 100mg